Pfizer has formed a collaboration with IBM Watson Health that will use the Watson for Drug Discovery cloud-based cognitive tool for research into immuno-oncology. Pfizer will customize the cloud-based cognitive tool to tap into IBM Watson’s machine learning, natural language processing, and other cognitive reasoning technologies to support the identification of new drug targets, combination therapies for study, and patient selection strategies in immuno-oncology.

The newly launched Watson for Drug Discovery cloud-based offering was developed to aid life sciences researchers to discover drug targets and alternative drug indications. The system analyzes high volumes of data, understands complex questions posed in natural language, and proposes evidence-based answers, according to IBM Watson.

Source: Pfizer